Because both EGFR and K-ras mutations are thought to be early events in lung adenocarcinoma [38] and K-ras mutations are closely related to smoking status [39], the reported coexistence of EGFR and K-ras mutations only accounts for about 5% of patients with EGFR mutations [40]. Here, KRAS is linked to lung adenocarcinoma.